TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05072106
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).
Study: NCT05833958
Drug: GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As described previously
Study: NCT05833958
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As described previously - Experimental Arm, 175mg at night
Study: NCT05833958
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As described previously - Active Comparator Arm, 500mg in the morning and 500mg at night
Study: NCT05580822
Drug: Tenecteplase for Injection
Normalized name: Tenecteplase for Injection
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intra-arterial TNK infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
Study: NCT05580822
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intra-arterial saline infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
Study: NCT06139341
Drug: BI 765845
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 765845
Study: NCT06361563
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As per product label
Study: NCT03850704
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002018
Drug: Interferon alfa-n3
Normalized name: Interferon alfa-n3
DrugBank: Interferon alfa-n3 (DB00018)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04712669
Drug: rodatristat ethyl 300 mg tablet BID
Normalized name: telotristat ethyl
DrugBank: Rodatristat (DB18478)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: rodatristat ethyl 300 mg tablet + matching placebo tablet twice daily on top of standard of care
Study: NCT04712669
Drug: rodatristat ethyl 600 mg BID
Normalized name: Ethyl acetate
DrugBank: Rodatristat (DB18478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 rodatristat ethyl 300 mg tablets twice daily on top of standard of care
Study: NCT06237751
Drug: Sildenafil 100 MG
Normalized name: sildenafil 100 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 100mg orally half an hour before surgery
Study: NCT05030077
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib(12mg) oral daily for days 1-14, 21 days per cycle
Study: NCT05030077
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (70 mg/m2) IV day 1
Study: NCT05030077
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If the patients can't tolerate cisplatin, they will be treated with carboplatin (AUC 4.5mg/mL·min) IV day 1
Study: NCT05030077
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine ( 1000 mg/m2) IV days 1 and 8
Study: NCT01630915
Drug: Torrent's Clopidogrel Tablets USP 75 mg
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05857371
Drug: autologous ADSVF administration
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADSVF will be administrated in fibrotic lesion during urethrotomy by the urologist.
Study: NCT05936489
Drug: Aceclidine + Brimonidine
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution
Study: NCT05936489
Drug: Aceclidine
Normalized name: Aceclidine
DrugBank: Aceclidine (DB13262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNZ100 (Aceclidine) non-preserved ophthalmic solution
Study: NCT04692623
Drug: Moxifloxacin 400mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
Study: NCT04692623
Drug: Gemifloxacin 320 MG
Normalized name: gemifloxacin 320 MG
DrugBank: Gemifloxacin (DB01155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
Study: NCT06353282
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA will be dosed in pre-filled capsules and administered orally to participants in two fixed doses - an 80mg dose following the fourth session and a 120mg dose following the ninth session of MDMA to each participant. MDMA experimental medication administration session 1 (8 hours); MDMA experimental medication session 2 (8 hours). Participants will be required to remain in the therapy room for the duration of the experimental medication sessions without the youths' parent/guardian present. The parent/guardian will be invited to attend integration sessions and must be available to drop off and pick up the participant.
Study: NCT06376630
Drug: Esmolol Hcl 10Mg/Ml Inj
Normalized name: ESMOLOL HCL 10MG/ML INJ
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the loading dose of 500 mkg/kg for 1 minute, followed by the initial rate of 50 mkg/kg/min. Individual titration depending on the desired hemodynamical effect (to the heart rate of 60 bpm or to the maximum tolerated dose maintaining stable hemodynamics) every 5-15 minutes (the maximum allowed rate of administration is 300 mkg/kg/min) for 6 hours.~Thereafter patients in both treatment arms - the IV esmolol arm and the placebo arm, will be administered oral β-adrenergic blockers, if decided so by the treating physician and unless contraindicated.
Study: NCT06131385
Drug: intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis using thrombolytic drugs such as ateplase and teneplase.
Study: NCT05800223
Drug: Almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage is 110 mg/day (2 tablets/day) orally once a day
Study: NCT05424016
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mg/d propranolol started in a progressive way (with control of Blood Pressure and heart rate during the consultations) neurosurgical consultation and an MRI every six months
Study: NCT06424444
Drug: Reproxalap ophthalmic solution (0.25%)
Normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproxalap ophthalmic solution (0.25%) administered QID for four weeks, followed by BID administration for two weeks
Study: NCT06424444
Drug: Vehicle ophthalmic solution
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ophthalmic solution administered QID for four weeks, followed by BID administration for two weeks
Study: NCT06423456
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.
Study: NCT06423456
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.
Study: NCT01876355
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.
Study: NCT01876355
Drug: SodiumChloride
Normalized name: Dextrose 2.5% and 0.45% SodiumChloride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
Study: NCT05397769
Drug: Envafolimab Plus Chemoradiotherapy
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
Study: NCT05390099
Drug: Moringa oleifera leaf
Normalized name: MORINGA OLEIFERA LEAF
DrugBank: Moringa oleifera leaf (DB14362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa toothpaste
Study: NCT06504368
Drug: DCR-PDL1
Normalized name: DCR-PHXC free acid
DrugBank: Nedosiran (DB17635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for IV Infusion
Study: NCT04969627
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Use Metformin for 3 months to treat PCOS
Study: NCT04969627
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use Exenatide for 3 months to treat PCOS
Study: NCT06153394
Drug: Redesca (enoxaparin sodium for injection)
Normalized name: enoxaparin sodium Injectable Solution
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Redesca is low molecular weight heparin and a biosimilar biologic drug (biosimilar) to Lovenox. Indications have been granted on the basis of similarity between Redesca and the reference biologic drug Lovenox. As such, Redesca (enoxaparin sodium) is indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield.
Study: NCT06153394
Drug: Fragmin (dalteparin)
Normalized name: dalteparin Injection [Fragmin]
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin is a low molecular weight heparin indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield. Our institution uses this drug for standard of care thromboprophylaxis (30 days) in this patient population.
Study: NCT00000646
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05742477
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: role of antibiotics in treatment of neonatal sepsis
Study: NCT05884268
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients scheduled for elective LC will receive 150 mg venlafaxine before surgery
Study: NCT05300958
Drug: Deferoxamine Plus Chemotherapy
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine：50mg/kg+500ml normal saline (NS)
Study: NCT04559555
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The compassionate use dose of nilotinib is 400 mg orally twice daily and should not be taken with food
Study: NCT00012506
Drug: TNFR:Fc
Normalized name: rhu TNFR:Fc
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06259058
Drug: Irinotecan liposome injection
Normalized name: Irinotecan liposome injection
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/m² on Day 1 of a 14-day cycle
Study: NCT06259058
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/m² on Day 1 of a 14-day cycle
Study: NCT06259058
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2400 mg/m² continuous IV infusion in 46 h
Study: NCT05218369
Drug: IL6 Antagonist
Normalized name: IL6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive IL-6 antagonist therapy at the consultant's discretion.
Study: NCT06339151
Drug: Dexamethasone before surgery
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 0.15 mg/kg IV before surgery
Study: NCT06339151
Drug: Dexamethasone before and 12 hours after surgery
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 0.15 mg/kg IV before surgery Dexamethasone 0.15 mg/kg IV at 12 hours post operation
Study: NCT06339151
Drug: Dexamethasone before and 24 hours after surgery
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 0.15 mg/kg IV before surgery Dexamethasone 0.15 mg/kg IV at 24 hours post operation
Study: NCT05925686
Drug: Tramadol.
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers.
Study: NCT00349583
Drug: Topical Cyclosporine, Tears
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05180695
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.
Study: NCT06318897
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT06318897
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV
Study: NCT06318897
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV
Study: NCT04199728
Drug: Liraglutide Pen Injector
Normalized name: liraglutide Pen Injector
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide will be provided using an injection pen provided by the manufacturer
Study: NCT05691881
Drug: 68Ga-NY105
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY105
Study: NCT06195891
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06195891
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06195891
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given tacrolimus
Study: NCT06195891
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06242041
Drug: sodium zirconium cyclic silicate
Normalized name: SODIUM SILICATE
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On the non-dialysis day, the drug was given to patients in the treatment group, four times a week, starting from 5g/day each time, and the blood potassium before dialysis was maintained at 4.0-5.0mmol/L, which could be adjusted at 10g/week each time, and the highest dose could be increased to 80g/ week.
Study: NCT04752475
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide 20 mg pill taken daily for 5 days
Study: NCT05201404
Drug: Namodenoson
Normalized name: Namodenoson
DrugBank: Namodenoson (DB12885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine A3 Receptor (A3AR) agonist
Study: NCT04532372
Drug: Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05745311
Drug: The KPCXM18 injection
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04296019
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with fruquintinib ( 5 mg qd for 3 consecutive weeks, followed by discontinuation for 1 week).
Study: NCT06192849
Drug: Furmonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
Study: NCT06079333
Drug: dabrafenib/trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: braf/mek-inhibition
Study: NCT05455424
Drug: Niraparib Oral Product
Normalized name: niraparib Oral Product
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib (\[3S\]-3-\[4-\[7-(aminocarbonyl)-2H-indazol-2-yl\] phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, and highly selective PARP1 and PARP2 inhibitor. The excipients for niraparib are lactose monohydrate and magnesium stearate. Niraparib will be supplied in bottles containing 72 capsules of 100 mg. The capsules should be swallowed whole with water. The capsules should not be chewed or crushed and can be taken without regard to meals.
Study: NCT05371925
Drug: Sulodexide
Normalized name: sulodexide
DrugBank: Sulodexide (DB06271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 250LRU sulodexide capsule twice a day for 8 weeks
Study: NCT06304636
Drug: Descartes-15
Normalized name: Descartes 30
DrugBank: Descartes-30 (DB16361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
Study: NCT00491413
Drug: epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05756504
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection Tramadol 25-50 mg IV x TDs wil be given to each patient in this group. Maximum dose will be 400 mg/ day
Study: NCT04983537
Drug: Gam-COVID-Vac / Gam-COVID-Vac
DrugBank: Gam-COVID-Vac (DB15848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
Study: NCT06493981
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with eltrombopag in a dose of (50-150mg/d)
Study: NCT05061563
Drug: Elinzanetant (BAY3427080)
Normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elinzanetant given orally as single dose capsule and intravenous as single dose in Period 1. Elinzanetant given orally as single dose capsule in Period 2.
Study: NCT05826275
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1 checkpoint blockade
Study: NCT05061563
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole given orally once daily for 5 days in Period 2.
Study: NCT05932277
Drug: BMS-986419
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05932277
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05932277
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05932277
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05932277
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06194734
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks